Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
McLaren Flint Regional Medical Center
mi
from
Flint, MI
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
McLaren Flint Regional Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Mount Sinai Health System
mi
from
New York, NY
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Mount Sinai Health System
mi
from
New York, NY
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Vassar Brothers Medical Center
mi
from
Poughkeepsie, NY
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Vassar Brothers Medical Center
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Valley Baptist Harlingen
mi
from
Harlingen, TX
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Valley Baptist Harlingen
mi
from
Harlingen, TX
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Toronto Western Hospital
mi
from
Toronto, Ontario,
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Toronto Western Hospital
mi
from
Toronto, Ontario,
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
St. Joseph's Hospital and Medical Center - Dignity Health (BNI Phoenix)
mi
from
Phoenix, AZ
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
St. Joseph's Hospital and Medical Center - Dignity Health (BNI Phoenix)
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Baptist Medical Center Jacksonville
mi
from
Jacksonville, FL
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Baptist Medical Center Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
University of Iowa
mi
from
Iowa City, IA
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Maine Medical Center
mi
from
Portland, ME
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Drexel University
mi
from
Philadelphia, PA
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Scripps Memorial Hospital
mi
from
La Jolla, CA
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Scripps Memorial Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Center for Advanced Research Excellence (St. Mary's Medical Center)
mi
from
West Palm Beach, FL
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Center for Advanced Research Excellence (St. Mary's Medical Center)
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated:  1/9/2018
Houston Methodist Hospital
mi
from
Houston, TX
Trevo® Retriever Registry Post Market Surveillance
Stryker Neurovascular Trevo® Retriever Registry
Status: Enrolling
Updated: 1/9/2018
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
The Lean Meats Mediterranean Diet Study
Effects of Incorporating Red Meat Into a Mediterranean-style Dietary Pattern on Cardiometabolic and Emotional Well-being
Status: Enrolling
Updated:  1/9/2018
Purdue University - Stone Hall 700 W State St
mi
from
West Lafayette, IN
The Lean Meats Mediterranean Diet Study
Effects of Incorporating Red Meat Into a Mediterranean-style Dietary Pattern on Cardiometabolic and Emotional Well-being
Status: Enrolling
Updated: 1/9/2018
Purdue University - Stone Hall 700 W State St
mi
from
West Lafayette, IN
Click here to add this to my saved trials
The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise
The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise
Status: Enrolling
Updated:  1/9/2018
Purdue University
mi
from
West Lafayette, IN
The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise
The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise
Status: Enrolling
Updated: 1/9/2018
Purdue University
mi
from
West Lafayette, IN
Click here to add this to my saved trials
Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft
Intracranial Atherosclerosis and Predictors of Post-CABG Depression
Status: Enrolling
Updated:  1/12/2018
Yale University School of Medicine
mi
from
New Haven, CT
Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft
Intracranial Atherosclerosis and Predictors of Post-CABG Depression
Status: Enrolling
Updated: 1/12/2018
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft
Intracranial Atherosclerosis and Predictors of Post-CABG Depression
Status: Enrolling
Updated:  1/12/2018
Johns Hopkins University
mi
from
Baltimore, MD
Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft
Intracranial Atherosclerosis and Predictors of Post-CABG Depression
Status: Enrolling
Updated: 1/12/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Status: Enrolling
Updated:  1/16/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Status: Enrolling
Updated: 1/16/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Egg Intake and Risk of Type 2 Diabetes
Egg Intake and Risk of Type 2 Diabetes in a Low Meat Intake Population
Status: Enrolling
Updated:  1/16/2018
Loma Linda University
mi
from
Loma Linda, CA
Egg Intake and Risk of Type 2 Diabetes
Egg Intake and Risk of Type 2 Diabetes in a Low Meat Intake Population
Status: Enrolling
Updated: 1/16/2018
Loma Linda University
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia
Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease
Status: Enrolling
Updated:  1/17/2018
Baylor Jack and Jane Hamilton Heart Hospital
mi
from
Dallas, TX
Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia
Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease
Status: Enrolling
Updated: 1/17/2018
Baylor Jack and Jane Hamilton Heart Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia
Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease
Status: Enrolling
Updated:  1/17/2018
Baylor Regional Medical Center at Plano
mi
from
Plano, TX
Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia
Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease
Status: Enrolling
Updated: 1/17/2018
Baylor Regional Medical Center at Plano
mi
from
Plano, TX
Click here to add this to my saved trials
Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia
Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease
Status: Enrolling
Updated:  1/17/2018
The Heart Hospital Baylor Plano
mi
from
Plano, TX
Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia
Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease
Status: Enrolling
Updated: 1/17/2018
The Heart Hospital Baylor Plano
mi
from
Plano, TX
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Birmingham, AL
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Birmingham, AL
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Huntsville, AL
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Mobile, AL
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Anchorage, AK
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Anchorage, AK
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Glendale, AZ
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Glendale, AZ
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Tucson, AZ
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Alhambra, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Alhambra, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Banning, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Banning, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Encino, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Escondido, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Harbor City, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Harbor City, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Huntington Beach, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Laguna Hills, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Long Beach, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Long Beach, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Los Alamitos, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Newport Beach, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Newport Beach, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Oceanside, CA
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials